Besides the treatment with insulin, treatment with sodium glucose transporter 2 (SGLT2) inhibitors has gained more importance related to randomized controlled trials for HF patients with and without concomitant DM II [40,41,42,43]. This evidence concerns the gene SLC5A2 and hydrops fetalis.